Instrument Inactif

Communiqués LipoScience Inc

Actions

US53630M1080

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

Communiqués

02/10/14	LipoScience : INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of LipoScience, Inc. Concerning the Fairness of the Sale of the Company to LabCorp	BU
29/09/14	LipoScience : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
26/09/14	LipoScience : Ryan & Maniskas, LLP : Announces Investigation of LipoScience, Inc.	PR
25/09/14	LipoScience : Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of LipoScience, Inc. Stockholders	BU
12/08/14	LipoScience Announces 2014 Second Quarter Financial Results	GL
04/08/14	LipoScience to Release Second Quarter 2014 Financial Results	GL
24/06/14	LipoScience : Study Published in Atherosclerosis Provides First Large-Scale, Real-World Evidence of Link Between Low LDL Particle Levels and Reduced Risk of Cardiovascular Disease	PU
14/06/14	LipoScience : NMR-based Diabetes Risk Index (DRI) Helps to Identify Normal-weight Individuals at High Risk of Progressing to Type 2 Diabetes	PU
02/05/14	LipoScience : Outcomes Study Supports Use of LDL Particle Number to Guide Statin Therapy in Patients at Elevated Cardiovascular Risk	PR
31/03/14	LipoScience : Patients Managed to Target LDL Particle Number Experience Fewer Cardiovascular Events Than Patients Managed to Target LDL Cholesterol, According to Study	PU
14/03/14	LipoScience : to Release Fourth Quarter and Fiscal Year 2013 Financial Results	PU
14/03/14	LipoScience : to Present at Barclays Global Healthcare Conference	PU
14/03/14	LipoScience : Announces 2013 Fourth Quarter and Full Year Financial Results	PU
22/01/14	LipoScience Announces Appointment of Howard Doran as President and Chief Executive Officer	GL
27/11/13	LipoScience Inc : LipoScience to Present at 25th Annual Piper Jaffray Healthcare Conference	PU
25/11/13	LipoScience Inc : LipoScience Announces Agreement With Scripps Health For First California Placement Of Vantera® Clinical Analyzer	PR
21/11/13	LipoScience Inc : LipoScience to Discuss 2014 Guidance on Fourth Quarter 2013 Financial Results Conference Call	PU
18/11/13	LipoScience Inc : Real-World Data Presented At AHA Scientific Sessions Demonstrate Relationship Between Low-Density Lipoprotein Particle (LDL-P) Number And Future Risk Of Coronary Heart Disease	PU
05/11/13	LipoScience Inc : LipoScience Reports Third Quarter 2013 Financial Results	PU
22/10/13	LipoScience Inc : LipoScience to Release Third Quarter Fiscal Year 2013 Financial Results	PU
06/09/13	LipoScience Inc : LipoScience Announces Appointment Of William Cromwell, M.D., As Chief Medical Officer	PU
04/09/13	LipoScience Inc : LipoScience Announces New Data Supporting High-Density Lipoprotein Particle (HDL-P) Number As Marker Of Cardiovascular Risk	PR
09/08/13	LipoScience Inc : LipoScience Announces Appointment Of Vice President, General Counsel And Corporate Secretary	PR
29/07/13	LipoScience Inc : LipoScience Announces Agreement With ARUP Clinical Laboratories For Placement Of Vantera® Clinical Analyzer	PR
19/06/13	LipoScience Inc : Analysis Demonstrates Cost-Effectiveness Of Managing Low-Density Lipoprotein Particle Number To Reduce Cardiovascular Disease Risk	PR